Move over Ahmed Fahour: when it comes to hefty remuneration, Clinuvel Pharmaceuticals chief Dr Philippe Wolgen may, in time, give the former chief postie a run for his money.

At the company's November 20 AGM in Melbourne, details of which were released on Friday, the board will ask its concentrated register to approve a grant of 1,513,750 performance rights (or 3.1 per cent of the company) to Wolgen. These would vest into that number of shares (for free) should certain hurdles be met. Or more easily, if the company changes hands. Their face value, at Friday's $31.85 share price, is $48.2 million.